Nabriva Therapeutics plc (NASDAQ: NBRV) reported a net loss of $23.3 million for Q1 2020, compared to $20.2 million in Q1 2019. Revenue decreased by $0.9 million to $0.8 million, primarily due to reduced collaboration revenues. The company's cash runway has been extended into Q4 2020, aided by prudent expense management. Managed care coverage for XENLETA is robust, covering nearly 70% of U.S. lives. However, future sales remain uncertain due to the COVID-19 pandemic. Nabriva aims for European approval of XENLETA and is restructuring its sales force.
Nabriva Therapeutics (NASDAQ: NBRV) announced a post-hoc analysis published in Open Forum Infectious Diseases, demonstrating that lefamulin achieves comparable time to clinical response and discharge readiness as moxifloxacin in hospitalized patients with community-acquired bacterial pneumonia (CABP). The study analyzed 926 patients, showing a median response time of 4 days for both treatments. Lefamulin's potential to enable early discharges could enhance cost-effectiveness in treating CABP, addressing significant safety concerns associated with fluoroquinolones.